Prevalence of human papillomavirus infection and phylogenetic analysis of HPV-16 E6 variants among infected women from Northern Brazil

Infectious Agents and Cancer

Rodrigo Vellasco Duarte Silvestre¹  Wyller Alencar de Mello¹  Carlos Gil Ferreira²  Fabio Passetti²  Edivaldo Costa Sousa-Júnior¹  Bruna Pedroso Tamegão-Lopes¹ 

[1] Laboratório de Papilomavírus, Seção de virologia, Instituto Evandro Chagas, Rodovia BR 316 km 07, Ananindeua, Pará, Brazil;Instituto Nacional de Câncer (INCA), Clinical Research Coordination, Rua André Cavalcanti, 37, 20231-050 Rio de Janeiro, RJ, Brazil

关键词: Variants;    HPV-16;    HPV;    Prevalence;   

Others  :  1161167
DOI  :  10.1186/1750-9378-9-25

 received in 2014-03-14, accepted in 2014-07-08,  发布年份 2014

【 摘 要 】

Background

The main cause of cervical cancer in the world is high risks human papillomavirus infection (mainly represented by HPV-16 and HPV-18), that are associated to the development of malign transformation of the epithelium. HPV prevalence exhibits a wide geographical variability and HPV-16 variants have been related to an increased risk of developing cervical intraepithelial lesion. The aim of this study was to describe DNA-HPV prevalence and HPV-16 variants among a women population from Northern Brazil.

Methods

One hundred and forty three women, during routine cervical cancer screening, at Juruti Project, fulfilled an epidemiological inquiry and were screened through a molecular HPV test. HPV-16 variants were determined by sequencing the HPV-16 E6 open reading frame.

Results

Forty two samples were considered HPV positive (29.4%). None of those had abnormal cytology results. HPV prevalence varied between different age groups (Z(U) = 14.62; p = <0.0001) and high-risk HPVs were more frequent among younger ages. The most prevalent type was HPV-16 (14%) and it variants were classified, predominantly, as European (87.5%).

Conclusions

HPV prevalence in our population was higher than described by others and the most prevalent HPV types were high-risk HPVs. The European HPV-16 variant was the most prevalent among HPV-16 positive samples. Our study reinforces the fact that women with normal cytology and a positive molecular test for high-risk HPVs should be submitted to continuous follow up, in order to verify persistence of infection, promoting an early diagnosis of cervical cancer and/or its precursors.

【 授权许可】

   
2014 Tamegão-Lopes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Stanley M: Immunobiology of HPV and vaccines. Gynecol Oncol 2009, 109:S15-S21.
• [2]De Villiers E-M: Cross-roads in the classification of papillomaviruses. Virology 2013, 445:2-10.
• [3]Gross G, Pfister H: Role of human papillomaviruses in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol 2004, 193:35-44.
• [4]Castellsagué X: Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008, 110:S4-S7.
• [5]Chopjitt P, Ekalaksananan T, Pietong C, Kongyingyoes B, Kleebkaow P, Charoensri N: Prevalence of human papillomavirus type 16 and its variants in abnormal squamous cervical cells in Northeast Thailand. Int J Infect Dis 2009, 13:212-219.
• [6]Frazer I: Correlating immunity with protection for HPV infection. Int J Infect Dis 2007, 11(suppl. 1):S10-S16.
• [7]Tornesello ML, Duraturo ML, Giorgi-Rossi P, Sansone M, Piccoli R, Buonaguro L, Buonaguro FM: Human papillomavirus (HPV) genotypes and HPV16 variants in human immunodeficiency virus-positive Italian women. J Gen Virol 2008, 89:1380-1389.
• [8]Fernandes JV, Meissner RV, Carvalho MGF, Fernandes TAAM, Azevedo PRM, Villa LL: Prevalence of HPV infection by cervical cytologic status in Brazil. Int J Gynaecol Obstet 2009, 105:21-24.
• [9]Zuna RE, Tuller E, Wentzensen N, Mathews C, Allen RA, Shanesmith R, Dunn ST, Gold MA, Wang SS, Walker J, Schiffman M: HPV16 variant lineage, clinical stage, and survival in women with invasive cervical cancer. Infect Agent Cancer 2011, 6:1-9.
• [10]Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in, GLOBOCAN 2008. Int J Cancer 2008, 2010(127):2893-2917.
• [11]Chen Z, Schiffman M, Herrero R, DeSalle R, Anastos K, Segongy M, Sahasrabuddhe VV, Gravitt PE, Hsing AW, Burk RD: Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV-16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67. PLoS One 2011, 6(5):e20183.
• [12]Alencar TR, Cerqueira DM, Cruz MR, Wyant PS, Ramalho ED, Martins CRF: New HPV-16 European and non-European variants in Central Brazil. Virus Genes 2007, 35:1-4.
• [13]Huertas-Salgado A, Martín-Gámez DC, Moreno P, Murillo R, Bravo MM, Villa L, Molano M: E6 molecular variants of human paillomavirus (HPV) type 16: An updated and unified criterion for clustering and nomenclatura. Virol 2011, 410:201-215.
• [14]Trottier H, Mahmud S, Prado JCM, Sobrinho JS, Costa MC, Rohan TE, Villa L, Franco EL: Type-Specific Duration of Human Papillomavirus Infection: Implications for Human Papillomavirus Screening and Vaccination. J Infect Dis 2008, 197:1436-1447.
• [15]Cornet I, Gheit T, Franceschi S, Vignat J, Burk RD, Sylla BS, Tommasino M, Clifford GM, IARC HPV Variant Study Group: Human Papillomavirus Type 16 Genetic Variants: Phylogeny and Classification Based on E6 and LCR. J Virol 2012, 86(12):6855-6861.
• [16]de SanJosé S, Diaz M, Castellsagué X, Clifford G, Bruni L, Muñoz N, Bosch FX: Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis 2007, 7:453-459.
• [17]Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S: Cervical Human Papillomavirus Prevalence in 5 Continents: Meta-Analysis of 1 Million Women with Normal Cytological Findings. J Infect Dis 2010, 202(12):1789-1799.
• [18]Rocha DAP, Filho RAAB, Queiroz AF, Santos CMB: High Prevalence and Genotypic Diversity of the Human Papillomavirus in Amazonian Women, Brazil. Infect Dis Obstet Gynecol 2013, ID514859:1-5.
• [19]Coser J, Rocha Boeira T, Simon D, Kazantzi Fonseca AS, Ikuta N, Lunge VR: Prevalence and genotypic diversity of cervical human papillomavirus infection among women from an urban Center in Brazil. Genet Mol Res 2013, 12(4):4276-4285.
• [20]Lippman SA, Sucupira MCA, Jones HE, Luppi CG, Palefsky J, van de Wijgert JHHM, Oliveira RLS, Dias RS: Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women. Int J STD AIDS 2010, 21(2):105-109.
• [21]Oliveira-Silva M, Lordello CX, Zardo LMG, Bonvicino CR, Moreira MAM: Human Papillomavirus in Brazilian women with and without cervical lesions. Virol J 2011, 8:1-4.
• [22]Smith JS, Melendy A, Rana RK, Pimenta JM: Age-Specific Prevalence of Infection with Human Papillomavirus in Females: A Global Review. J Adolesc Health 2008, 43:S5-S25.
• [23]Franceschi S, Herrero R, Clifford GM, Snijders PJF, Arslan A, Anh PTH, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, Qiao Y-L, Rajkumar R, Ronco G, de Sanjosé S, Shin H-R, Sukvirach S, Thomas JO, Meijer CJLM, Muñoz N, the IARC HPV Prevalence Surveys Study Group: Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer 2006, 119:2677-2684.
• [24]Brismar-Wendel S, Froberg M, Hjerpe A, Anderson S, Johansson B: Age-specific prevalence of HPV genotypes in cervical cytology samples with equivocal or low-grade lesions. Br J Cancer 2009, 101:511-517.
• [25]Baussano I, Franceschi S, Gillio-Tos A, Carozzi F, Confortini M, Palma PD, de Lillo M, del Mistro A, de Marco L, Naldoni C, Pierotti P, Schincaglia P, Segnan N, Zorzi M, Giorgi-Rossi P, Ronco G: Difference in overall and age-specific prevalence of high-risk human papillomavirus infection in Italy: evidence from NTCC Trial. BMC Infect Dis 2013, 13:238.
• [26]IARC Working Group on the Evaluation of Carcinogenic Risks to Human: A review of human carcinogens. Part B: Biological agents. Lyon, France; 2009.
• [27]Fernandes JV, Meissner RV, Carvalho MGF, Fernandes TAAM, Azevedo PRM, Sobrinho JS, Prado JCM, Villa LL: Prevalence of human papillomavirus in archival samples obtained from patients with cervical pre-malignant and malignant lesions from Northeast Brazil. BMC Res Notes 2010, 3:96.
• [28]Junes-Gill K, Sichero L, Maciag PC, Mello W, Noronha V, Villa LL: Human Papillomavirus Type 16 Variants in Cervical Cancer from an Admixtured Population in Brazil. J Med Virol 2008, 80:1639-1645.
• [29]Villa L, Sichero L, Rahal P, Caballero O, Ferenczy A, Rohan T, Franco EL: Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. J Gen Virol 2000, 81:2959-2968.
• [30]Zehbe I, Lichtig H, Westerback A, Lambert PF, Tommasino M, Sherman L: Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential. Mol Cancer 2011, 10:1-13.
• [31]Muñoz N, Franco EL, Herrero R, Andrus JK, de Quadros C, Goldie SJ, Bosch FX: Recommendations for Cervical Cancer Prevention in Latin America and the Caribbean. Vaccine 2008, 26S:L96-L107.
• [32]Bernard H-U, Calleja-Macias IE, Dunn ST: Genome variation of human papillomavirus types: Phylogenetic and medical implications. Int J Cancer 2006, 118:1071-1076.
• [33]Sichero L, Ferreira S, Trottier H, Duarte-Franco E, Ferenczy A, Franco EL, Villa LL: High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18. Int J Cancer 2007, 120:1763-1768.
• [34]Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL: Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24S3:S3/26-S3/34.
• [35]Kurman RJ, Solomon D: The Bethesda System for Reporting Cervical/Vaginal Cytologic Diagnoses Definitions, Criteria, and Explanatory Notes for Terminology and Specimen Adequacy. ISBN: 978-0-387-94077-9 (Print) 978-1-4684-0201-8 (Online). Springer- Verlag, New York Inc. 1994
• [36]BioEstat 5.3, Instituto de Desenvolvimento Sustentável Mamirauá 2011. [cited 2011 Sep 16]. Available from: http://www.mamiraua.org.br/download/ webcite